FDA Inspection 1241654 — Nordmark Pharma GmbH

Nordmark Pharma GmbH — FEI 3003293533

The FDA completed an inspection of Nordmark Pharma GmbH on August 31, 2023 in Uetersen. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 31, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Uetersen (Germany)

Additional Details

Mutual Recognition Agreement (MRA)